Selicrelumab - Roche
Alternative Names: RG-7876; RO-7009789Latest Information Update: 05 Nov 2023
At a glance
- Originator Roche
- Developer Abramson Cancer Center of the University of Pennsylvania; Lymphoma Academic Research Organisation; Roche
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer; Solid tumours
- Discontinued Non-Hodgkin's lymphoma
Most Recent Events
- 26 Jul 2021 The Lymphoma Academic Research Organisation and Roche terminates phase I trial in Non-Hodgkin's lymphoma (Combination therapy, Recurrent, Refractory metastatic disease, Second-line therapy or greater) in France (Intratumoural) (NCT03892525)
- 23 Jul 2021 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Combination therapy, Recurrent, Refractory metastatic disease, Second-line therapy or greater) in France (Intratumoural)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Pancreatic-cancer in USA (IV)